Immunome, Inc. (IMNM)

Market Cap	607.79M
Revenue (ttm)	9.04M
Net Income (ttm)	-292.96M
Shares Out	86.95M
EPS (ttm)	-5.00
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,060,122
Open	7.23
Previous Close	7.28
Day's Range	6.90 - 7.39
52-Week Range	6.90 - 24.87
Beta	1.94
Analysts	Strong Buy
Price Target	26.60 (+280.54%)
Earnings Date	Mar 19, 2025

About IMNM

Immunome, Inc., a clinical-stage biotechnology company, develops targeted cancer therapies. The company’s clinical asset comprises of AL102, a gamma secretase inhibitor which is in phase 3 clinical trial for the treatment of desmoid tumors; IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates which is in phase 1 clinical trial; and preclinical asset consist of IM-3050, a fibroblast activation protein targeted radioligand therapy. It also develops solid tumor ADC drug candidates which includes IM-1617, IM-1340,...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 2, 2020
• Employees: 55
• Stock Exchange: NASDAQ
• Ticker Symbol: IMNM
• Website: https://immunome.com

Financial Performance

In 2024, Immunome's revenue was $9.04 million, a decrease of -35.50% compared to the previous year's $14.02 million. Losses were -$292.96 million, 174.3% more than in 2023.

Analyst Forecast

According to 5 analysts, the average rating for IMNM stock is "Strong Buy." The 12-month stock price forecast is $26.6, which is an increase of 280.54% from the latest price.

Price Target

$26.6

(280.54% upside)

Analyst Consensus: Strong Buy